SCHEMBL3633399

SCHEMBL3633399

CCCC(=O)c1ccc(NCc2csc(C)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.49
SMN1; SMN2 Q16637 6/20 0.49
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 2/20 0.45
MAPT P10636 4/20 0.44
GAA P10253 1/20 0.43
HSD17B3 P37058 1/20 0.43
FRK P42685 1/20 0.43
CAMK2B Q13554 1/20 0.43
CAMK2G Q13555 1/20 0.43
CAMK2D Q13557 1/20 0.43
SLC27A1 Q6PCB7 1/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
PKM P14618 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666322 0.85 ADORA2A (0.41) TP53SMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3639184 0.83 HPGD (0.52) SMN1; SMN2RAB9ANPC1MAPTSLC27A1
SCHEMBL3633928 0.81 RHOC (0.49) TP53SMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3635050 0.81 SCD (0.46) TP53SMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3638167 0.79 KDM4C (0.44) SMN1; SMN2ALDH1A1MAPTGAAHSD17B3
SCHEMBL3634440 0.79 FRK (0.58) TP53SMN1; SMN2MAPTFRKCAMK2B
SCHEMBL3637928 0.78 SUCNR1 (0.49) SMN1; SMN2RAB9AALDH1A1MAPTGAA
SCHEMBL3639374 0.78 FRK (0.44) SMN1; SMN2RAB9AALDH1A1GAAHSD17B3
SCHEMBL3640559 0.78 FRK (0.42) TP53SMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3637976 0.78 FRK (0.44) SMN1; SMN2RAB9AALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 TP53 4848/4885SMN1; SMN2 1228/4885RAB9A 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.